TY - JOUR
T1 - The role of component-resolved diagnosis in Hymenoptera venom allergy
AU - Bilò, Maria B.
AU - Ollert, Markus
AU - Blank, Simon
N1 - Funding Information:
MBB has received speaker’s honorarium and consultancy fees from ALK-Abelló. MO reports personal fees from Thermo Fisher Phadia, personal fees from Siemens Healthcare Diagnostics, personal fees from Hitachi Chemical Diagnostics, personal fees from Hycor, outside the submitted work; and is Scientific co-founder of the university biotech spin-off PLS-Design GmbH, Hamburg, Germany. SB reports nonfinancial support from ALK-Abelló, grants, personal fees and nonfinancial support from Bencard Allergie GmbH, personal fees from Teomed AG, grants and personal fees from Thermo Fisher Scientific, grants from Allergy Therapeutics, outside the submitted work.
Publisher Copyright:
© 2019 E-flow Lippincott Williams and Wilkins. All rights reserved.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Purpose of reviewComponent-resolved diagnostics (CRD) is a new tool aiming at detecting IgE-mediated sensitizations against individual, relevant allergens. Here, we discuss recent literature on molecular diagnosis in the field of Hymenoptera venom allergy (HVA) as well as CRD strengths and weaknesses.Recent findingsCRD, using single molecules or panels of allergens, may discriminate between primary sensitization and cross-reactivity in patients with double/multiple positivity in diagnostic tests with whole extracts, allowing the specialist to choose the most suitable venom for specific immunotherapy (VIT), avoiding unnecessary VIT and reducing the risk of side effects. Future availability of the cross-reactive recombinant pairs of allergens of different species may further increase the diagnostic performance. CRD may be useful in patients with negative allergy tests and a proven history of a previous systemic reaction, including those with mast cell disorders, who could benefit from VIT. In honeybee venom allergy, different sensitization profiles have been identified, which could be associated with a greater risk of VIT failure or treatment side effects.SummaryCRD is undoubtedly an innovative diagnostic method that leads to a more precise definition of the sensitization profile of the HVA patient. Together with a better knowledge of the molecular composition of different venom extracts, CRD may contribute to optimize patient-tailored therapy.
AB - Purpose of reviewComponent-resolved diagnostics (CRD) is a new tool aiming at detecting IgE-mediated sensitizations against individual, relevant allergens. Here, we discuss recent literature on molecular diagnosis in the field of Hymenoptera venom allergy (HVA) as well as CRD strengths and weaknesses.Recent findingsCRD, using single molecules or panels of allergens, may discriminate between primary sensitization and cross-reactivity in patients with double/multiple positivity in diagnostic tests with whole extracts, allowing the specialist to choose the most suitable venom for specific immunotherapy (VIT), avoiding unnecessary VIT and reducing the risk of side effects. Future availability of the cross-reactive recombinant pairs of allergens of different species may further increase the diagnostic performance. CRD may be useful in patients with negative allergy tests and a proven history of a previous systemic reaction, including those with mast cell disorders, who could benefit from VIT. In honeybee venom allergy, different sensitization profiles have been identified, which could be associated with a greater risk of VIT failure or treatment side effects.SummaryCRD is undoubtedly an innovative diagnostic method that leads to a more precise definition of the sensitization profile of the HVA patient. Together with a better knowledge of the molecular composition of different venom extracts, CRD may contribute to optimize patient-tailored therapy.
KW - Hymenoptera venom allergy
KW - allergy diagnostics
KW - anaphylaxis
KW - systemic reactions
KW - venom immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85074551832&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/31343438
U2 - 10.1097/ACI.0000000000000574
DO - 10.1097/ACI.0000000000000574
M3 - Review article
C2 - 31343438
AN - SCOPUS:85074551832
SN - 1528-4050
VL - 19
SP - 614
EP - 622
JO - Current Opinion in Allergy and Clinical Immunology
JF - Current Opinion in Allergy and Clinical Immunology
IS - 6
ER -